Skip to main content
. Author manuscript; available in PMC: 2009 Jun 29.
Published in final edited form as: J Neuroimmunol. 2008 Apr 10;195(1-2):140–145. doi: 10.1016/j.jneuroim.2008.01.002

Figure 3. Chemokine production by CD46-activated mDCs.

Figure 3

(A) The productions of CCL2, CCL3 and CCL5 by mature mDCs obtained by culture with LPS in presence or absence of CD46 antibodies were measured by qPCR (A) in a cohort of 8 healthy donors and 9 untreated patients with MS in the relapsing-remitting phase. Their relative expression compared to immature mDCs is plotted. (B) The amounts of CCL2, CCL3 and CCL5 secreted by mDC activated by CD46 (or irrelevant IgG1) were assessed by ELISA.